Podcasts about bioscience

Brian Stolz has cracked the code — literally and figuratively — on what it takes to build thriving teams in biotech. Episode 110 of The Hennessy Report by Keystone Partners features Brian Stolz, Chief People Officer at Element Biosciences, joined by Keystone Partners West Coast Market Leader Charlene Hutchins. Brian shares how growing up in Tokyo shaped his global perspective, his philosophy on building high-performing teams through diversity of thought, and how Element Bio's culture is rooted in respect, authenticity, and collaboration. He also dives into how AI is transforming HR and talent management, why the bio life sciences industry is poised for a major turnaround, and what he sees driving investment in the sector heading into 2026. Plus, Keystone's Vicky Rayel closes out the episode with practical career development advice in Coach's Corner.

What happens when science education is designed as a relational, exploratory process rather than a rigid set of steps? In this episode, Claire de Mezerville López and Nikki Chamblee welcome science educator and restorative practitioner Kate Shapero to the Restorative Pedagogies series of the Restorative Works! Podcast to examine how restorative practices can transform the science classroom. Kate reflects on curiosity, experimentation, and learning from mistakes as essential elements of scientific thinking—and how these processes depend on trust, emotional safety, and strong relationships. Through stories from her classroom, she illustrates how student-led exploration, play, and collaborative problem-solving foster both scientific understanding and social-emotional growth. The conversation explores how restorative practices support risk-taking, perseverance, and teamwork in scientific inquiry, while also developing communication and relational skills that extend beyond the classroom. Kate invites educators to see restorative practices not as separate from content, but as integral to how students learn, collaborate, and engage deeply with science and with one another. Kate Shapero is a Science Education and Restorative Practices Specialist with over 20 years of experience. After completing her undergraduate degree, she developed and taught science curriculum in independent and alternative schools in the Philadelphia area. Working with pre-K through postgraduate learners, she specializes in progressive curriculum design that is experiential, meaningful, and joyful. As a restorative practitioner, Kate collaborates with students, teaching teams, classroom communities, parent groups, and administrative staff to improve community relational health. Kate's current work includes facilitation, coaching, and professional development. She earned a Bachelor of Science in Bioscience and Biotechnology from Drexel University in 2003 and a Master of Restorative Practices and Education from the IIRP Graduate School in 2010. Tune in to explore how integrating restorative practices into lesson plans can transform the science classroom.

Ashley Beckwith is the founder and CEO of Foray Bioscience, where she and her team leverage plant cell culture to createpredictable access to the plants and plant products the world needs, by growing them from the cell up. Ashley's path into the world of plants has been a curious one. She holds a Ph.D. in Mechanical Engineering from MIT and hasbeen innovating at the intersection of biology, materials, and manufacturing for over a decade. Her award-winning Ph.D. research led to the first demonstration of lab-grown “wood”, combining principles of tissue engineering and plant culture to grow structured plant materials in the lab. Now, Ashley leads Foray's team of plant biologists, process engineers, software developers, and machine learningexperts to make plant cell and tissue culture predictable and accessible for applications from micropropagation to fabricated seed production. 

For this episode, we are joined by Amy Toth, Professor in Ecology, Evolution, and Organismal Biology at Iowa State University, and Matt O'Neal, a Wallace Chair for Sustainable Agriculture and Professor in the Plant Pathology, Entomology, and Microbiology Department, also at Iowa State University. They were here to discuss their article from BioScience's forthcoming special issue on One Health, entitled, "Can Native Vegetation in Agroecosystems Provide a Net Benefit for Pollinators, Despite Pesticide Use?" 

Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF, FRA:WQ5) CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about the company's latest RNS regarding its upcoming AGM and the strategic rationale behind authorising the potential issuance of shares ahead of clinical partnership discussions. Leire addressed potential shareholder concerns, acknowledging that announcements involving share issuance can sometimes be interpreted as a fundraising signal. However, he clarified that the RNS is not about launching a capital raise, but about strengthening the company's position in ongoing and future negotiations with major pharmaceutical partners. He explained that in biotech, financial flexibility translates directly into leverage. “In biotech, cash is not just money, it's negotiating power,” Leire said. As a public company, Genflow's financial position is visible to potential partners, and Leire emphasised the importance of maintaining the ability to walk away from unfavourable terms. He added that the company is not committing to using the full 38% share issuance authority and stressed that the underlying science remains unchanged. “Our science has not changed. What we're doing is just making sure that we capture the full value of our science,” he noted. While acknowledging that markets dislike uncertainty, Leire stated that uncertainty is temporary, whereas signing a bad deal would have lasting consequences. He said the company is focused on optimising for the best long-term outcome and ensuring it is not forced into a suboptimal agreement. For more updates like this, visit Proactive's YouTube channel, give this video a like, subscribe to the channel and enable notifications so you don't miss future content. #GenflowBiosciences #BiotechNews #BiotechInvesting #PharmaPartnership #LifeSciences #AGMUpdate #HealthcareStocks #ClinicalPartnerships #SmallCapStocks #UKBiotech

Join hosts Kieren Sharma (Artificially Ever After podcast, University of Bristol) and Andrew Page (MicroBinfie podcast, Origin Sciences) for a compelling live panel discussion exploring the dynamic intersection of artificial intelligence and the biosciences. In this episode, our expert panel discusses:

The world faces mounting pressure to accelerate sustainable innovation at the intersection of food, health and industrial production, but moving from scientific discovery to scaled impact remains complex. From improving crop resilience and reducing environmental footprints to building healthier communities and more sustainable supply chains, bioscience innovations have become critical tools in tackling global sustainability challenges. This webinar, hosted by Innovation Forum in partnership with the Iowa Economic Development Authority explored how some of the latest bioscience breakthroughs are addressing these pressing issues. We look at emerging trends shaping the next wave of sustainable innovation, the technologies driving impact, and how organisations are applying bioscience. As a case study, we examined how Iowa is emerging as a key hub for the biosciences, bringing together agriculture technology, medical innovation, and industrial biotechnology in one ecosystem. What we discussed… Which bioscience breakthroughs from the past year are driving measurable sustainability impact, and how they came about What to watch for in 2026: scaling technologies, new applications, and the role of advanced technology in enabling sustainable innovation What drives success in biosciences: fostering innovation internally, building strategic partnerships, and leveraging ecosystems to deliver sustainable solutions

GreenLight Biosciences' Jonathan Adamson says they've shown that RNA can be a viable solution to control the pests that potato growers deal with regularly.

January 29, 2026: Your daily rundown of health and wellness news, in under 5 minutes. Today's top stories: Sword Health acquires Kaia Health for $285M, expanding AI Care platform into Germany's 70M+ person reimbursement system Flo Health and Mayo Clinic study finds U.S. women lag behind UK, Canada, and Australia in recognizing perimenopause symptoms Life Biosciences receives FDA clearance for first human trial of partial cellular reprogramming, targeting glaucoma using gene therapy More from Fitt: Fitt Insider breaks down the convergence of fitness, wellness, and healthcare — and what it means for business, culture, and capital. Subscribe to our newsletter → insider.fitt.co/subscribe Work with our recruiting firm → https://talent.fitt.co/ Follow us on Instagram → https://www.instagram.com/fittinsider/ Follow us on LinkedIn → linkedin.com/company/fittinsider Reach out → insider@fitt.co

In this episode of Skin Anarchy, Dr. Ekta Yadav sits down with Dr. Tiffany Libby for a clear, science-forward conversation on supplements, cellular energy, and why NAD biology has become such a focal point in modern longevity discussions. As interest in “aging better” grows, this episode cuts through hype to explore what NAD optimization can—and cannot—realistically do for skin and whole-body health.Dr. Libby brings a rare perspective to the conversation. As a board-certified dermatologist and Director of Mohs Surgery at Brown University Health, her work spans both skin cancer care and cosmetic dermatology, treating patients across decades of life. That long view has shaped her understanding of longevity not as youth preservation, but as maintaining resilience, repair capacity, and function over time—especially in the face of inflammation, environmental stress, and chronic disease.Much of the discussion centers on why supplements, particularly NAD boosters, are having a cultural moment. Dr. Libby explains that this surge reflects a gap in the healthcare system itself—one that prioritizes treatment over prevention. While supplements can offer support, she emphasizes they are not shortcuts. Longevity still rests on fundamentals: sleep, nutrition, movement, stress regulation, and inflammation control.The episode offers a practical breakdown of NAD (nicotinamide adenine dinucleotide), explaining its role in mitochondrial energy production, DNA repair, and cellular defense. As NAD levels decline with age, skin becomes less efficient at repairing damage, producing collagen, and maintaining barrier integrity. Crucially, Dr. Libby explains why NAD itself can't be absorbed directly—and why precursors like nicotinamide riboside (NR) matter instead.Throughout the conversation, skepticism and safety remain central themes. In an underregulated supplement space, quality, dosing, and clinical validation matter. From a dermatologic standpoint, supporting mitochondrial health may help skin function closer to its biological potential—but only when paired with evidence-based care and realistic expectations.Listen to the full episode of Skin Anarchy to hear Dr. Tiffany Libby unpack the science of NAD, cellular energy, and why longevity begins with supporting biology—not chasing promises.SHOP TRU NIAGENDon't forget to subscribe to Skin Anarchy on Apple Podcasts, Spotify, or your preferred platform.Reach out to us through email with any questions.Sign up for our newsletter!Shop all our episodes and products mentioned through our ShopMy Shelf!Support the show

We love to hear from our listeners. Send us a message.Welcome to episode 120 of Cell & Gene: The Podcast. Host Erin Harris is joined by Rachel Haurwitz, CEO of Caribou Biosciences, to discuss the company's progress in developing CRISPR-edited, off-the-shelf CAR-T therapies for hematologic malignancies. Their conversation centers on Vispacell, Caribou's allogeneic CD19 CAR-T for second-line large B-cell lymphoma. Haurwitz explains how Caribou has systematically optimized its allogeneic platform using clinical and translational data. They also cover pivotal Phase 3 trial planning, regulatory considerations, and what to expect next from Caribou's broader pipeline, including its BCMA-targeted program in multiple myeloma.Subscribe to the podcast!Apple | Spotify | YouTube Visit my website: Cell & Gene Connect with me on LinkedIn

Guy Wilson visits with Tom and Jason in Starkville as a Platinum sponsor of the 2025 Row Crop Short Course.  Find out more at https://www.greenlightbiosciences.com/ For more episodes from the Crop Doctors, visit our website at http://extension.msstate.edu/shows/mississippi-crop-situation

Todd Harris, CEO and Co-Founder of Tyra Biosciences, is focused on developing a selective inhibitor for FGFR3, a protein implicated in bladder cancer and childhood dwarfism. The company has developed the SNAP discovery platform to accelerate structure-based drug design targeting this specific protein, while avoiding effects on related proteins to minimize significant side effects. Their lead drug candidate has the potential to become a primary well-tolerated oral monotherapy, shifting the treatment paradigm for cancer patients to prevent recurrence and for children to allow for more typical bone growth. Todd explains, "We are taking a novel step to a set of conditions, genetic conditions in FGFR3 biology that have long been known, that others have attempted to address, but where the underlying chemistry hasn't had the necessary selectivity to really be able to make progress. FGFR3 biology is implicated both in bladder cancer and in kids with dwarfism and short stature conditions. And there have long been chemical matter drugs that can inhibit FGFR3, but also inhibit close family members, including FGFR1 and 2. These close family members, the nature of the close family members, make it very challenging to make a drug that is a drug candidate that selectively inhibits FGFR3 while sparing FGFR1, 2, and 4."   "And it was a challenge we took on because we felt like we could meaningfully improve the outcomes for patients by doing so. FGFR3 has important biology in bone and cancer, but FGFR1 and 2 have important biology as well and can lead to side effects when inhibited at the same time as FGFR3. So our attempt to make a selective inhibitor is really an effort to minimize off-target tolerability effects, things that can affect, like pain in your nails, blistering of hands and feet, and elevated phosphate levels when taking the pan FGFR drugs. And then just focus on a drug that can inhibit FGFR3, avoid that type of toxicity, and be able to more meaningfully impact these genetic conditions." #TyraBio #TyraBiosciences #PrecisionMedicine #BladderCancer #RareDiseases #Achondroplasia #Biotechnology #DrugDevelopment #FGFR3 #Innovation #ClinicalTrials #Oncology #PediatricMedicine #StructureBasedDrugDesign tyra.bio Download the transcript here 

Todd Harris, CEO and Co-Founder of Tyra Biosciences, is focused on developing a selective inhibitor for FGFR3, a protein implicated in bladder cancer and childhood dwarfism. The company has developed the SNAP discovery platform to accelerate structure-based drug design targeting this specific protein, while avoiding effects on related proteins to minimize significant side effects. Their lead drug candidate has the potential to become a primary well-tolerated oral monotherapy, shifting the treatment paradigm for cancer patients to prevent recurrence and for children to allow for more typical bone growth. Todd explains, "We are taking a novel step to a set of conditions, genetic conditions in FGFR3 biology that have long been known, that others have attempted to address, but where the underlying chemistry hasn't had the necessary selectivity to really be able to make progress. FGFR3 biology is implicated both in bladder cancer and in kids with dwarfism and short stature conditions. And there have long been chemical matter drugs that can inhibit FGFR3, but also inhibit close family members, including FGFR1 and 2. These close family members, the nature of the close family members, make it very challenging to make a drug that is a drug candidate that selectively inhibits FGFR3 while sparing FGFR1, 2, and 4."   "And it was a challenge we took on because we felt like we could meaningfully improve the outcomes for patients by doing so. FGFR3 has important biology in bone and cancer, but FGFR1 and 2 have important biology as well and can lead to side effects when inhibited at the same time as FGFR3. So our attempt to make a selective inhibitor is really an effort to minimize off-target tolerability effects, things that can affect, like pain in your nails, blistering of hands and feet, and elevated phosphate levels when taking the pan FGFR drugs. And then just focus on a drug that can inhibit FGFR3, avoid that type of toxicity, and be able to more meaningfully impact these genetic conditions." #TyraBio #TyraBiosciences #PrecisionMedicine #BladderCancer #RareDiseases #Achondroplasia #Biotechnology #DrugDevelopment #FGFR3 #Innovation #ClinicalTrials #Oncology #PediatricMedicine #StructureBasedDrugDesign tyra.bio Listen to the podcast here 

For this episode, we're joined by journalist Paul Koberstein, who was here to discuss his first book, Canopy of Titans, which is about the connection between forests and climate. In particular, the book focuses on the Pacific Coastal Temperate Rainforest, which constitutes one of the world's most important carbon stores. You can read recent expose on timber industry misinformation here.  

Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF) CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about the company's key programs and upcoming catalysts as it enters what management expects to be a pivotal year. Leire discussed why 2026 is shaping up as “a year of catalysts” for the company, with particular focus on the dog ageing trial, progress in MASH, and the group's approach to partnerships and licensing. Leire explained that the dog longevity study is the nearest catalyst, with the trial expected to be unblinded shortly and early efficacy readouts anticipated in the near term. While safety has already been confirmed, the study remains blinded, meaning efficacy results are still unknown. The first data will focus on biological age, measured using a methylation clock, with a more detailed analysis of muscle biopsies and mitochondrial function to follow. According to Leire, “this trial could be very important for our shareholders, because it will trigger a deal with an animal health company bringing non-dilutive money in the company.” The interview also explored Genflow's repositioning in MASH toward advanced fibrosis and the prevention of hepatocellular carcinoma. Leire highlighted the significant unmet need in late-stage disease, noting that recent therapies target earlier stages and leave patients with advanced fibrosis facing limited options. He said the company's preclinical data have been encouraging and form a key part of the IND package, helping differentiate Genflow from existing and emerging treatments. In addition, Leire discussed the company's licensing strategy, including plans to out-license the dog program to an animal health specialist and pursue early-stage partnerships for glaucoma, while retaining focus on age-related conditions such as sarcopenia. With meetings planned during JPMorgan week, Leire said the company is seeking non-dilutive capital and strategic validation as it moves forward. For more interviews like this, visit Proactive's YouTube channel, give the video a like, subscribe to the channel, and enable notifications so you don't miss future updates. #GenflowBiosciences #GENF #GENFF #Biotechnology #LongevityResearch #DogAging #AnimalHealth #MASH #LiverDisease #Fibrosis #BiotechStocks #LifeSciences #LicensingDeals #JPmorganHealthcare

In this special holiday replay episode, we revisit our conversation with Ashley Beckwith, founder of Foray Biosciences, who shares her groundbreaking work in plant cell culture and tissue engineering. Growing up in Colorado, Ashley watched forests disappear to housing development and wildfire—experiences that sparked her lifelong mission to reimagine how we produce plant materials. After training as an engineer and working in medical device development, she pivoted to apply tissue engineering concepts to plants, initially exploring lab-grown wood before discovering a more fundamental problem: the lack of accessible, efficient plant cell culture processes. Today, Foray develops fabricated seeds for forest restoration, creates harvest-free plant products, and builds AI-powered tools to accelerate plant science R&D. Ashley explains why plant cells are the fundamental building blocks for everything from molecules to materials to entire ecosystems, and how her company is working to solve the seed shortage crisis that prevents us from restoring 94% of post-wildfire sites. She also discusses the potential for de-extinction of recently lost plant species in California and the importance of creating regenerative rather than extractive relationships with plant systems. This conversation explores the intersection of synthetic biology, forestry, and biomanufacturing while reminding us that we are all, whether we know it or not, plant people.Grow Everything brings the bioeconomy to life. Hosts Karl Schmieder and Erum Azeez Khan share stories and interview the leaders and influencers changing the world by growing everything. Biology is the oldest technology. And it can be engineered. What are we growing?Learn more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.messaginglab.com/groweverything⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Chapters:(00:00:00) - Holiday Greetings and Stranger Things on Broadway(00:04:41) - Introducing Ashley Beckwith and Foray Biosciences(00:07:17) - Growing Up in Colorado: Watching Forests Disappear(00:10:48) - From Medical Engineering to Plant Biology(00:15:00) - The Lab-Grown Wood Experiment(00:18:58) - Understanding Plant Cells as Versatile Production Agents(00:25:00) - Fabricated Seeds for California Biodiversity Restoration(00:33:00) - Addressing the Wildfire Restoration Seed Shortage(00:42:00) - Building the Plant Operating System with AI(00:50:00) - Why We're All Plant PeopleLinks and Resources:Foray Biosciences⁠⁠SF500 (Argentinian Global Venture Fund)⁠⁠Syensqo Corporate Venture Fund⁠⁠H.C. Wainwright⁠⁠University of Vermont - Dr. Steve Keller⁠⁠University of Maryland - Dr. Matt FitzpatrickForay Biosciences154. No Trees Were Harmed: Symmetry Wood's Gabe Tavas on Growing Wood from WasteTopics Covered: developmental biology, morphology, morphospace, planarians, electroceuticals, bioelectricity, tissue regeneration, biomedical applications, holidays, ChristmasHave a question or comment? Message us here:Text or Call (804) 505-5553 ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  / ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Twitter⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Youtube⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Grow Everything⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Email: groweverything@messaginglab.comMusic by: NihiloreProduction by: Amplafy Media

For this episode, we were joined by Scott Spillias, who is a Research Scientist at CSIRO and affiliated with the Centre for Marine Socioecology at the University of Tasmania, and Beth Fulton, who is Chief Research Scientist with CSIRO and the Deputy Director of the Center for Marine Socioecology. We spoke about their recent BioScience article "The Future of Artificial Intelligence in Ecosystem Modeling." 

Peter Godfrey-Smith, Professor of History and Philosophy of Science at the University of Sydney, explores the evolutionary roots of consciousness by surveying animal evolution and the emergence of felt experience in several lineages. He examines two central philosophical questions: how such experience might arise gradually, existing in partial forms, and whether it represents a single unified feature with variations or instead a cluster of distinct traits. Author of "Darwinian Populations and Natural Selection," and "Living on Earth: Forests, Corals, Consciousness and the Making of the World," Godfrey-Smith brings his expertise in philosophy of biology and mind to illuminate how consciousness may have emerged and why its origins remain a profound puzzle. Series: "UC Berkeley Graduate Lectures" [Humanities] [Science] [Show ID: 41065]

Peter Godfrey-Smith, Professor of History and Philosophy of Science at the University of Sydney, explores the evolutionary roots of consciousness by surveying animal evolution and the emergence of felt experience in several lineages. He examines two central philosophical questions: how such experience might arise gradually, existing in partial forms, and whether it represents a single unified feature with variations or instead a cluster of distinct traits. Author of "Darwinian Populations and Natural Selection," and "Living on Earth: Forests, Corals, Consciousness and the Making of the World," Godfrey-Smith brings his expertise in philosophy of biology and mind to illuminate how consciousness may have emerged and why its origins remain a profound puzzle. Series: "UC Berkeley Graduate Lectures" [Humanities] [Science] [Show ID: 41065]

Peter Godfrey-Smith, Professor of History and Philosophy of Science at the University of Sydney, explores the evolutionary roots of consciousness by surveying animal evolution and the emergence of felt experience in several lineages. He examines two central philosophical questions: how such experience might arise gradually, existing in partial forms, and whether it represents a single unified feature with variations or instead a cluster of distinct traits. Author of "Darwinian Populations and Natural Selection," and "Living on Earth: Forests, Corals, Consciousness and the Making of the World," Godfrey-Smith brings his expertise in philosophy of biology and mind to illuminate how consciousness may have emerged and why its origins remain a profound puzzle. Series: "UC Berkeley Graduate Lectures" [Humanities] [Science] [Show ID: 41065]

Peter Godfrey-Smith, Professor of History and Philosophy of Science at the University of Sydney, explores the evolutionary roots of consciousness by surveying animal evolution and the emergence of felt experience in several lineages. He examines two central philosophical questions: how such experience might arise gradually, existing in partial forms, and whether it represents a single unified feature with variations or instead a cluster of distinct traits. Author of "Darwinian Populations and Natural Selection," and "Living on Earth: Forests, Corals, Consciousness and the Making of the World," Godfrey-Smith brings his expertise in philosophy of biology and mind to illuminate how consciousness may have emerged and why its origins remain a profound puzzle. Series: "UC Berkeley Graduate Lectures" [Humanities] [Science] [Show ID: 41065]

Peter Godfrey-Smith, Professor of History and Philosophy of Science at the University of Sydney, explores the evolutionary roots of consciousness by surveying animal evolution and the emergence of felt experience in several lineages. He examines two central philosophical questions: how such experience might arise gradually, existing in partial forms, and whether it represents a single unified feature with variations or instead a cluster of distinct traits. Author of "Darwinian Populations and Natural Selection," and "Living on Earth: Forests, Corals, Consciousness and the Making of the World," Godfrey-Smith brings his expertise in philosophy of biology and mind to illuminate how consciousness may have emerged and why its origins remain a profound puzzle. Series: "UC Berkeley Graduate Lectures" [Humanities] [Science] [Show ID: 41065]

Peter Godfrey-Smith, Professor of History and Philosophy of Science at the University of Sydney, explores the evolutionary roots of consciousness by surveying animal evolution and the emergence of felt experience in several lineages. He examines two central philosophical questions: how such experience might arise gradually, existing in partial forms, and whether it represents a single unified feature with variations or instead a cluster of distinct traits. Author of "Darwinian Populations and Natural Selection," and "Living on Earth: Forests, Corals, Consciousness and the Making of the World," Godfrey-Smith brings his expertise in philosophy of biology and mind to illuminate how consciousness may have emerged and why its origins remain a profound puzzle. Series: "UC Berkeley Graduate Lectures" [Humanities] [Science] [Show ID: 41065]

Join Hedi Ben Brahim, CEO of One Biosciences and a leading figure in the French biotechnology ecosystem, in an in-depth conversation with Gary Fowler as they explore how single-cell technologies are transforming precision medicine. Learn how One Biosciences is unlocking new therapeutic targets, expanding to the U.S., and navigating the challenges of scaling an innovation-driven biotech company.Insights You'll Learn:✓ What single-cell analysis enables that traditional drug discovery cannot✓ How One Biosciences identifies new targets for difficult-to-treat diseases✓ Challenges and opportunities in expanding a European biotech to the U.S. market✓ Why computational biology is central to the next wave of precision therapeutics✓ How to build an integrated discovery engine combining wet lab and in-silico innovation✓ Lessons from leading biotech, oncology, and immunotherapy organizations✓ The current biotech landscape — and what founders must prepare for nextWhy This Matters:Single-cell technology is redefining how we understand disease at a molecular level. One Biosciences sits at the forefront of this revolution, combining computational power with multidisciplinary research to accelerate new therapies for complex conditions.Hedi's leadership—across public policy, oncology, immunotherapy, and biotech scaling—offers rare insight into what it takes to bring breakthrough science from Europe to the global stage.Expert Background:• Chief Executive Officer of One Biosciences• Former CEO of Transgene, a leader in immunotherapy and oncology• Veteran of France's Ministry of Economy and Ministry of Health• Held leadership roles across biotech, healthtech, and research institutes• Board member at GeNeuro and Kolibri• Recognized expert in precision medicine, oncology, and biotech innovationAbout One Biosciences:One Biosciences leverages advanced single-cell analysis to power a new wave of precision medicine. Its integrated discovery engine fuses computational biology and multidisciplinary expertise to find therapeutic targets for complex, difficult-to-treat diseases. Supported by Institut Curie and Home Biosciences, it is accelerating breakthroughs in drug discovery.

In this episode of Data in Biotech, Ross Katz chats with Wesley Tatum, Principal Engineer at Serán BioScience, about the intricacies of formulating low-solubility drug products. They explore the science behind amorphous solid dispersions, how data informs formulation choices, and why balancing performance, manufacturability, and stability is critical in modern drug development. What you'll learn in this episode: >> How amorphous solid dispersions improve solubility and stability in drug products >> Why formulation decisions hinge on early data collection and modeling >> The role of data infrastructure in formulation R&D and knowledge transfer >> How Serán BioScience collaborates closely with clients to solve complex drug development challenges >> Where AI and automation are (and aren't yet) transforming pharmaceutical formulation Meet our guest Wesley Tatum is a Materials Science PhD researcher working at the crossroads of materials innovation, data science, and machine learning. His work focuses on organic materials and polymer dispersions, and he's especially passionate about how modern computational tools can transform the way we characterize and understand new materials. Wesley is well versed in PyTorch, Scikit-Learn, and a range of open-source scientific computing libraries, and he brings deep experience in chemical analysis, microscopy, and image analysis.  About The Host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with Wesley Tatum on LinkedIn  Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.

It is well known that inside nearly every living cell on this planet, there are instructions powering the dynamics of everything in the cell, known as deoxyribonucleic acid (DNA). Enoch Yeung, Associate Professor of Mechanical Engineering at UC, Santa Barbara, explains how DNA is the genetic code that tells cells where to live, how to live, and how to adapt when things get tough. Editing DNA has unlocked new potential in biology, enabled new therapeutics, diagnostics, and modes of treating diseases. Since DNA is double-stranded, it literally maintains a backup copy of itself to proof-read and facilitate stability of code. The double-stranded nature of DNA also means it can sometimes encode two messages in a given length! In short, DNA is amazing. Series: "GRIT Talks" [Science] [Show ID: 41040]

It is well known that inside nearly every living cell on this planet, there are instructions powering the dynamics of everything in the cell, known as deoxyribonucleic acid (DNA). Enoch Yeung, Associate Professor of Mechanical Engineering at UC, Santa Barbara, explains how DNA is the genetic code that tells cells where to live, how to live, and how to adapt when things get tough. Editing DNA has unlocked new potential in biology, enabled new therapeutics, diagnostics, and modes of treating diseases. Since DNA is double-stranded, it literally maintains a backup copy of itself to proof-read and facilitate stability of code. The double-stranded nature of DNA also means it can sometimes encode two messages in a given length! In short, DNA is amazing. Series: "GRIT Talks" [Science] [Show ID: 41040]

It is well known that inside nearly every living cell on this planet, there are instructions powering the dynamics of everything in the cell, known as deoxyribonucleic acid (DNA). Enoch Yeung, Associate Professor of Mechanical Engineering at UC, Santa Barbara, explains how DNA is the genetic code that tells cells where to live, how to live, and how to adapt when things get tough. Editing DNA has unlocked new potential in biology, enabled new therapeutics, diagnostics, and modes of treating diseases. Since DNA is double-stranded, it literally maintains a backup copy of itself to proof-read and facilitate stability of code. The double-stranded nature of DNA also means it can sometimes encode two messages in a given length! In short, DNA is amazing. Series: "GRIT Talks" [Science] [Show ID: 41040]

It is well known that inside nearly every living cell on this planet, there are instructions powering the dynamics of everything in the cell, known as deoxyribonucleic acid (DNA). Enoch Yeung, Associate Professor of Mechanical Engineering at UC, Santa Barbara, explains how DNA is the genetic code that tells cells where to live, how to live, and how to adapt when things get tough. Editing DNA has unlocked new potential in biology, enabled new therapeutics, diagnostics, and modes of treating diseases. Since DNA is double-stranded, it literally maintains a backup copy of itself to proof-read and facilitate stability of code. The double-stranded nature of DNA also means it can sometimes encode two messages in a given length! In short, DNA is amazing. Series: "GRIT Talks" [Science] [Show ID: 41040]

It is well known that inside nearly every living cell on this planet, there are instructions powering the dynamics of everything in the cell, known as deoxyribonucleic acid (DNA). Enoch Yeung, Associate Professor of Mechanical Engineering at UC, Santa Barbara, explains how DNA is the genetic code that tells cells where to live, how to live, and how to adapt when things get tough. Editing DNA has unlocked new potential in biology, enabled new therapeutics, diagnostics, and modes of treating diseases. Since DNA is double-stranded, it literally maintains a backup copy of itself to proof-read and facilitate stability of code. The double-stranded nature of DNA also means it can sometimes encode two messages in a given length! In short, DNA is amazing. Series: "GRIT Talks" [Science] [Show ID: 41040]

How much plastic are we actually absorbing and what's it doing to our health?In this eye-opening episode, I'm joined by Dr. Stephanie Wright, one of the UK's leading scientists in microplastic research, to explore what happens when plastic pollution doesn't just affect the environment, but our bodies too.We dive into:

For this episode, we're joined once again by John Van Stan, a Professor at Cleveland State University, in the Department of Biological, Geological, and Environmental Sciences. He also runs an independent press, The Press of a Ridiculous Man, which you can find on Amazon. Dr. Van Stan was here today to discuss his recent BioScience article "A cautionary tale about urban trees: could ecoservice monetary estimates become economic sleights of hand?"

Die Themen in den Wissensnachrichten: +++ Um immer mehr Vitalbereiche der Erde steht es schlecht +++ Widerspruchslösung sorgt nicht automatisch für mehr Organspenden +++ Deutsche Vogelwelt erlebt Wandel +++**********Weiterführende Quellen zu dieser Folge:The 2025 state of the climate report: a planet on the brink, BioScience, 29.10.2025Crowding-out effects of opt-out defaults: Evidence from organ donation policies, PNAS Nexus, 28.10.2025Wie zufrieden sind Ein- und Ausgewanderte? Deutschland im Fokus, BiB-Monitor Wohlbefinden 2025, 29.10.2025Vögel in Deutschland: Bestandssituation 2025, Bundesamt für Naturschutz, 28.10.2025Elevated virus infection of honey bee queens reduces methyl oleate production and destabilizes colony-level social structure, PNAS, 14.10.2025Alle Quellen findet ihr hier.**********Ihr könnt uns auch auf diesen Kanälen folgen: TikTok und Instagram .

For this episode, we were joined by members of the Biodiversity Collections Network, who discussed the NSF-funded BIOFAIR project, the subject of a recent Special Report in BioScience entitled, "Integrating biological and environmental data to solve key scientific and societal challenges." Learn more.

If you're a moth trying to stay uneaten, there are competing strategies. Some moths rely on camouflage, trying to blend in. Other moths take the opposite approach: They're bold and bright, with colors that say “don't eat me, I'm poison.” Biologist Iliana Medina joins Host Flora Lichtman to describe a study that placed some 15,000 origami moths in forests around the world to investigate which strategy might work best. Then, mammologist Anderson Feijó and evolutionary biologist Rafaela Missagia join Flora to dive into another evolutionary conundrum: why so many rodents have thumbnails. Guests: Dr. Iliana Medina Guzman is a Senior Lecturer in the School of BioSciences at the University of Melbourne in Australia.Dr. Anderson Feijó is a mammal curator at the Field Museum in Chicago. Dr. Rafaela Missagia is an assistant professor at the University of São Paulo in Brazil.Transcripts for each episode are available within 1-3 days at sciencefriday.com.  Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

Under Pressure, Leaders RiseWhen I spoke with Cyrill Kellerhals, COO of Andelyn Biosciences, I was struck by how calm and grounded he was while describing some of the toughest leadership moments of his career.At Novartis, he faced a difficult FDA inspection — the kind of moment that could make or break a company. Instead of panicking, he led his team through it and turned it into a success.Later, he carried those lessons into scaling a $34M operation and building a $200M biopharma facility. But what impressed me most wasn't the numbers — it was the way he talked about leading with humility, purpose, and service to his people.His story is a reminder that real leadership isn't about avoiding pressure. It's about how you show up when the stakes are highest.-----Follow Cyril: https://www.linkedin.com/in/cyrill-k-82a73152/Lean more about Andelyn Biosciences: https://www.andelynbio.com/-----Connect with the Host, #1 bestselling author Ben FanningSpeaking and Training inquiresSubscribe to my Youtube channelLinkedInInstagramTwitter

Love the episode? Send us a text!In this conversation, Laura Carfang interviews JP Parthasarathy, the founder and CEO of Astran Biosciences, about the critical topic of breast cancer, particularly focusing on breast density and its implications for women's health. They discuss the importance of understanding breast density, the advancements in early cancer detection technologies, and the ongoing clinical trials aimed at improving screening methods. JP shares insights into the science behind cancer progression, the risk factors associated with breast density, and the potential for blood tests to revolutionize cancer screening. The conversation emphasizes the need for personalized medicine and the importance of empowering patients with knowledge about their health risks.What you will learn: Breast density is a significant risk factor for breast cancer.Many women are unaware of their breast density and its implications.Early detection of cancer cells is crucial for effective treatment.Current mammogram technologies may not effectively detect cancers in dense breasts.Personalized screening programs can improve outcomes for high-risk individuals.The science of cancer progression is evolving, revealing new insights.Blood tests may provide a less invasive method for early cancer detection.Advocacy and awareness are key in improving women's health outcomes.Understanding individual risk factors can lead to better screening strategies.The future of cancer detection lies in integrating advanced technologies and personalized medicine.Attend a free virtual SurvivingBreastCancer.org program (support groups, yoga, medication, expressive writing, art expression, and more!):https://www.survivingbreastcancer.org/eventsSubscribe to our weekly newsletterhttps://www.survivingbreastcancer.org/subscribeFollow us on InstagramSurvivingBreastCancer.org: https://www.survivingbreastcancer.org/Breast Cancer Conversations: https://www.instagram.com/breastcancerconversations/Support our Podcast, every dollar counts! https://givebutter.com/0fCiEUSupport the showLatest News: Join our Tell Cancer To Go #TakeAHike October 25, 2025 fundraiser! It's free to sign up! Learn more and start your team! Become a Breast Cancer Conversations+ Member! Sign Up Now.

UC Davis students from multiple disciplines are learning to design enzymes that address challenges in food, energy and health. Through the Design2Data program, they gain hands-on experience in enzyme engineering, preparing for careers in science and research that make a real-world impact. See how our students contribute to solving important human needs. Series: "UC Davis News" [Science] [Show ID: 41052]

UC Davis students from multiple disciplines are learning to design enzymes that address challenges in food, energy and health. Through the Design2Data program, they gain hands-on experience in enzyme engineering, preparing for careers in science and research that make a real-world impact. See how our students contribute to solving important human needs. Series: "UC Davis News" [Science] [Show ID: 41052]

Is it the C-section? The formula? The antibiotics? Parents often wonder if they've messed up their baby's gut health. In this episode, Dr. Wendy talks with Stephanie Culler PhD, co-founder of Persephone Biosciences, about groundbreaking research on the infant microbiome. You'll learn why most American babies are missing Bifidobacterium infantis—the bacteria that digest special sugars in breast milk and help build the immune system—and how new science is bringing those microbes back through a product called a “synbiotic.”    Purchase Persephone Bloom and Thrive Product now on Peresphone Biosciences website! Send your questions to hello@pediatriciannextdoorpodcast.com or message me online here.  Find products from the show on the shop page.   *As an Amazon Associate, I earn commission from qualifying purchases.    More from The Pediatrician Next Door:    Website: Pediatrician Next Door Podcast  Instagram: @the_pediatrician_next_door  Facebook: facebook.com/wendy.l.hunter.75  TikTok: @drwendyhunter  LinkedIn: linkedin.com/in/drwendyhunter    This is a Redd Rock Music Podcast  IG: @reddrockmusic  www.reddrockmusic.com Learn more about your ad choices. Visit megaphone.fm/adchoices

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Novartis has increased its commitment to its partnership with Argo BioPharma by an additional $5.2 billion, focusing on RNAi agreements targeting cardiovascular diseases. This highlights the ongoing advancements and challenges in the biopharmaceutical industry. Biotechs are turning to special purpose acquisition companies (SPACs) as a way to go public amid the IPO freeze. Gene therapy, with its potential to cure deadly diseases, is still facing challenges in terms of insurance coverage in the U.S. The industry is seeing a shift with some of the biggest biotech SPACs from the 2021 bubble no longer on the market. Meanwhile, Cytokinetics' cardiac myosin inhibitor, aficamten, has shown promising results in a phase III study for patients with obstructive hypertrophic cardiomyopathy. RFK Jr. has announced plans to reorganize chronic disease programs in the US to address high COVID-19 death rates. Companies like Novartis and Arrowhead are making significant commitments to various programs, while Trump's efforts to shore up the pharma supply chain with U.S. API are being questioned. Novartis continues its cutting spree with layoffs in New Jersey.These developments shed light on the evolving landscape of the biopharmaceutical industry.

For this episode of BioScience Talks, we're joined by Diego Ellis Soto, a postdoctoral researcher at the University of California, Berkeley, and a research scientist at the California Academy of Science. He's an ecologist working at the intersection of technology, conservation, policy, and environmental justice. And there's even some music in the mix, as you'll soon hear.  You can find links to more of Dr. Ellis Soto's work on his personal website and more music on Spotify and SoundCloud. 

Todd Harris, CEO of Tyra Biosciences, shares his insights about leadership in biopharma and how Tyra is working to develop precision medicines that target large fibroblast growth factor receptor biology.

Colossal Laboratories & Biosciences has been in the news quite frequently in recent years. If you've heard the term "de-extinction" it was likely referring to their work. Colossal's Chief Animal Officer and Executive Director of the Colossal Foundation Matt James joins us in studio this week. We talk about Colossal's origin and growth into a [...]

Aron Knickerbocker, President and CEO of Aulos Bioscience,  is on a mission to extend the lives of cancer patients through safer and more effective immunotherapy using AI and machine learning to accelerate drug discovery and optimization. The company's lead drug candidate is an antibody that was designed using AI to harness the power of interleukin-2 to activate the immune system against tumors.  The advantages of AU-007 over previous IL-2 therapies include the ability to selectively activate tumor-fighting immune cells while avoiding toxicity due to vascular leakage. Current trials are underway in advanced melanoma and non-small cell lung cancer, which are showing the potential for durable responses and immune memory. Aron explains, "So Aulos has really been founded to carry out a mission to extend the lives of patients with innovative, safe, and ultimately effective cancer immunotherapy. And you mentioned IL-2, which is the naturally occurring protein that we're seeking to harness and redirect in productive ways to help the patients. And this has really been kind of a driver for me over the years, wanting to improve on cancer patient care. This is a company with an important mission and a great team, and our program is really interesting. It's harnessing IL-2 in such a way that it sends it to the cells that are capable of attacking the tumor and killing the tumor cells, and keeps it away from the cells that suppress the immune response. It's really kind of using a double-edged sword in a productive way to help patients with cancer." "So this is the first antibody to go into human clinical trials. It was designed in part by leveraging an AI platform, as you noted. And that platform was created by our collaborators at Biologic Design. They're the company that created this molecule. And what biologic design does is essentially using an AI system that has machine learning algorithms that drive it. It mimics what the immune system does normally. So when we get sick and we need to make antibodies to something, our immune system says, Do I already have something that will kind of bind to the target or the virus or whatever it's trying to hit? And then it will optimize that. It will go through a process of rapid change. And what the AI system and the machine learning algorithms that have been trained on millions of antibodies in the targets to which they bind do is recognize patterns much like an AI chatbot might recognize language patterns." #AulosBio #Antibodies #MedAi #AI #IL2 #Onocology #Cancer #NSCLC #AdvancedCutaneousMelanoma #DrugDiscovery #BiologicDesign #Tregs aulosbio.com Listen to the podcast here

***For 20% off your Solstice order, use code ABOVEANDBEYOND*****A note from Dr. Lewellis: We encountered a number of recording difficulties during this episode, which resulted in a mild echo and some transitions that can be hard to follow. My wonderful editing team did an excellent job cleaning and patching things up, but I do want my audience to be aware of it. I apologize in advance, and thanks as always for listening!**Episode 058 | Brett  Ozanich, DO, FAAD is a Board Certified Dermatologist and Micrographic Dermatologic Surgeon at Epiphany Dermatology in El Paso, Texas. He performs approximately 1500 Mohs cases per year as well as providing medical and cosmetic dermatology services.  In April of 2024, Brett and his wife, an anesthesiologist, conceptualized a skin-focused line of beverages that they named Solstice. In 2025, Solstice came to market with a glow-up in a can. Packed with powerhouse ingredients like polypodium leucotomos, zinc, niacinamide, and vitamins A, C, D, Solstice works in harmony with sunscreen and other sun protective measures to shield your skin from the inside out. Whether you're starting your day with the vibrant “Let's Glo” or winding down with the relaxing “After Hours,” every sip is designed to help you feel radiant and ready to shine.Dr. Ozanich received his Doctor of Osteopathic Medicine at Kansas City University of Medicine & Biosciences and completed Dermatology Residency at San Antonio Military Medical Center. He is a fellow of the American Academy of Dermatology (AAD) and the American Society of Mohs Surgery (ASMS), as well as an active member of the American Society of Dermatologic Surgery (ASDS), the Texas Dermatologic Society (TDS), and the Texas Medical Association (TMA). He is actively involved in medical student and physician-assistant student education as well as research/clinical trials.Dr. Lewellis does not have an ownership stake in Solstice to declare, and Solstice did not provide financial or other support for this episode, which was recorded on March 21st, 2025.Connect with and learn from Dr. Ozanich and SolsticeDr. Brett Ozanich at Epiphany DermatologySolstice — Drink Up. Glo Up.Solstice on InstagramMore from Dr. Lewellis and Above & Beyond DermatologyNeed a dermatologist? Fill out this short interest form, text or call me at 715-391-9774, or email me at drlewellis@aboveandbeyondderm.com if you'd like to have a no obligation discovery call. I offer in-office visits, house calls, and virtual care in Wisconsin and virtual care in Illinois, Nebraska, and Colorado.Have an idea for a guest or want to be on the show yourself? Send me a text or email, and we'll see if it's a good fit.Above & Beyond DermatologyNutrafol -- special pricing and physician exclusive productsNeoGenesis -- my favorite source of stem cell released molecules for skin/hairSilagen.biz -- physician dispensed scar refinement products delivered to your door (use practice code 1206240832P)NewsletterLinkedInFacebookDr. Lewellis on InstagramAbove & Beyond Dermatology on InstagramYouTubeTikTokTwitter/XChange Your Mind, Change Your LifeSoMeDocs (Doctors on Social Media)Pippa!

 James Lazarovits is the CEO and Co-Founder of Archon Biosciences, a leader at the intersection of materials engineering and artificial intelligence. James brings over 15 years of experience building, mentoring, and investing in deep tech startups across AI, software, hardware, and robotics. Before founding Archon, James was at the forefront of AI-driven computational protein design as a post-doctoral fellow and later research faculty at the Institute for Protein Design at the University of Washington, under the direction of 2024 Nobel Laureate, David Baker. There, he contributed to pioneering methods that integrate machine learning and molecular engineering to create next-gen therapeutic proteins. Jamie earned his PhD in nanotechnology engineering from the University of Toronto where he worked under Nanomedicine expert, Dr. Warren Chan. His doctoral work focused on overcoming biological delivery barriers, using nano materials and deep learning, laying the groundwork for his later contributions to rational protein design. See omnystudio.com/listener for privacy information.

On today's episode, hear from Jose Ramirez, director of agronomy at Impello Biosciences and speaker at the 2025 Crop Consultant Conference, about his upcoming session in September on the role of silicon in plant nutrition and abiotic stress.Supporting the People who Support AgricultureThank you to this month's sponsors who makes it possible to get you your daily news. Please feel free to visit their website.2025 Crop Consultant Conference - https://myaglife.com/crop-consultant-conference/

Colossal Laboratories & Biosciences: https://colossal.com Guests today: Dr. Beth Shapiro and Matt James. _______________________________________ If you appreciate my work and would like to support it: https://subscribestar.com/the-saad-truth https://patreon.com/GadSaad https://paypal.me/GadSaad To subscribe to my exclusive content on Twitter, please visit my bio at https://twitter.com/GadSaad _______________________________________ This clip was posted on May 5, 2025 on my YouTube channel as THE SAAD TRUTH_1850: https://youtu.be/jlfkuKSurcw _______________________________________ Please visit my website gadsaad.com, and sign up for alerts. If you appreciate my content, click on the "Support My Work" button. I count on my fans to support my efforts. You can donate via Patreon, PayPal, and/or SubscribeStar. _______________________________________ Dr. Gad Saad is a professor, evolutionary behavioral scientist, and author who pioneered the use of evolutionary psychology in marketing and consumer behavior. In addition to his scientific work, Dr. Saad is a leading public intellectual who often writes and speaks about idea pathogens that are destroying logic, science, reason, and common sense.  _______________________________________